Navigation Links
Researchers identify potential new strategy to treat ovarian cancer
Date:4/28/2014

Scientists studying cancerous tumour tissues in a laboratory believe they have identified a potential new strategy to treat ovarian cancer which affects around 7,000 women in the UK each year.

Recently developed drugs have increased patient survival rates by targeting a tumour's blood vessels that supply essential nutrients and oxygen to cancer cells.

However, many patients go on to develop resistance to these therapies and grow new blood vessels that spread the cancer again.

A team from The University of Manchester part of the Manchester Cancer Research Centre - say blocking several avenues that tumour cells use to escape eradication at the same time is now the way forward rather than current drugs, which target only one molecule.

The research gives scientists the opportunity to develop new anticancer drugs that target ovarian tumour growth through the inhibition of the development of new tumour blood vessels.

Ovarian cancer is the deadliest of all gynaecological cancers, and since the majority of patients are diagnosed when the disease is at an advanced stage, prognosis is generally poor. Currently 7,000 women are diagnosed with the disease in the UK each year. Of those, more than 4,000 are not expected to survive but if women are diagnosed earlier 90% of those cases could beat the disease.

Scientists looked at the role of a particular set of molecules in controlling the activity of growth factors, proteins that are responsible for the stimulation of blood vessel growth.

Dr Egle Avizienyte, who co-led the research with Professor Gordon Jayson, said: "We know that a molecule called heparan sulphate (HS) is involved in blood vessel growth through facilitating interactions between the growth factors and their receptors that induce the development of new blood vessels. This is controlled by proteins known as HS6STs which regulate HS structure. By knocking down these proteins reducing their levels in cancer cells we were able to reduce activity of growth factors and stop ovarian cancer cells inducing the development of new blood vessels."

The studies in tumour tissue in the laboratory showed that reducing HS6STs led to a reduction of tumour growth.

Professor Gordon Jayson, who leads the research group, said: "This knowledge gives us the opportunity to develop new anticancer drugs aimed against these growth factors. Targeting multiple factors and blocking several avenues that tumour cells use to escape eradication at the same time may be a better strategy than current drugs, which target only one molecule."


'/>"/>

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. NYU Steinhardt researchers to study why male millennials risk HIV transmission
2. Researchers generate immunity against tumor vessel protein
3. Researchers at LSTM part of the international team to sequence the tsetse genome
4. Oxygen diminishes the hearts ability to regenerate, researchers discover
5. Finnish team of researchers finds a mutation in a tumor of the jaw
6. Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches
7. Life stressors trigger neurological disorders, researchers find
8. Penn researchers find link between sleep and immune function in fruit flies
9. Penn Medicine researchers uncover hints of a novel mechanism behind general anesthetic action
10. CU researchers discover target for treating dengue fever
11. BUSM researchers find anti-seizure drug may reduce alcohol consumption
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology: